Clinical trial

Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral…

NCT02928497 · Boston Scientific Corporation, Industry · Completed

Key facts

NCT number NCT02928497
Title Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation
Official title Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO)
Acronym ASAP-TOO
Lead sponsor Boston Scientific Corporation, Industry
Status Completed
Study type Interventional
Conditions Stroke
Intervention type Device, Drug
Interventions WATCHMAN LAAC Device Implant, Single Antiplatelet Therapy or No Therapy (Control)
Enrollment 481
Start date Feb 6, 2017
Primary completion Sep 23, 2025
Completion Sep 23, 2025
First posted Oct 10, 2016
Last update posted Jan 20, 2026
Countries Belgium, Canada, Czechia, Denmark, Germany, Italy, Netherlands, United Kingdom, United States

At a glance

  • 100–999 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies